Equities Analysts Set Expectations for Sanofi’s Q3 2024 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities research analysts at Zacks Research lowered their Q3 2024 earnings per share estimates for Sanofi in a report released on Wednesday, August 14th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $1.31 for the quarter, down from their prior estimate of $1.37. The consensus estimate for Sanofi’s current full-year earnings is $4.18 per share. Zacks Research also issued estimates for Sanofi’s FY2024 earnings at $4.12 EPS, Q2 2025 earnings at $0.99 EPS, Q1 2026 earnings at $1.34 EPS and Q2 2026 earnings at $1.07 EPS.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.95 earnings per share.

Other analysts have also issued reports about the company. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $54.52 on Monday. The business’s 50-day moving average price is $50.41 and its 200-day moving average price is $48.86. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72. The firm has a market capitalization of $138.08 billion, a price-to-earnings ratio of 27.40, a PEG ratio of 1.55 and a beta of 0.59. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Institutional Trading of Sanofi

Several hedge funds have recently bought and sold shares of SNY. Point72 Asset Management L.P. bought a new position in Sanofi in the 2nd quarter valued at about $10,261,000. EP Wealth Advisors LLC raised its stake in shares of Sanofi by 23.1% in the second quarter. EP Wealth Advisors LLC now owns 5,347 shares of the company’s stock worth $259,000 after purchasing an additional 1,002 shares during the last quarter. Brandes Investment Partners LP lifted its holdings in shares of Sanofi by 8.4% in the second quarter. Brandes Investment Partners LP now owns 2,122,748 shares of the company’s stock valued at $102,706,000 after purchasing an additional 165,256 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Sanofi by 27.2% during the second quarter. NewEdge Advisors LLC now owns 29,587 shares of the company’s stock valued at $1,436,000 after buying an additional 6,330 shares during the last quarter. Finally, Creative Planning boosted its position in shares of Sanofi by 9.2% during the second quarter. Creative Planning now owns 187,035 shares of the company’s stock valued at $9,075,000 after buying an additional 15,749 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.